PSEN1 and acute lymphoblastic leukemia: While the development of non-specific γ-secretase inhibitors was hampered by toxicity, the presenilin-1 (PSEN1) subunit γ-secretase inhibitor has demonstrated activity in preclinical models of NOTCH-mutated T-ALL with minimal toxicity and may have therapeutic potential [25].